There was no statistical difference in the number of prior anti-VEGF intravitreal injection therapies (33 vs. 45, P = 0.591), but the agent differed between groups: Only PDR patients received ranibizumab injections (28 vs. 0, P = 0.044) and the majority of NPDR patients received Aflibercept injections (5 vs 45, P = 0.137). The gene discussed is VEGFA; the disease is non-proliferative diabetic retinopathy.